Ethyl 3-<4-<(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl)methoxy>phenyl>-2-chloropropionate | 97322-68-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: Ethyl 3-<4-<(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl)methoxy>phenyl>-2-chloropropionate
• 英文别名: ethyl 3-{4-[(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl)metoxy]phenyl}-2-chloropropionate；ethyl 3-[4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)phenyl]-2-chloropropionate；ethyl 3-[4-[(6-acetyloxy-2,5,7,8-tetramethyl-3,4-dihydrochromen-2-yl)methoxy]phenyl]-2-chloropropanoate
• CAS: 97322-68-4
• 化学式: C₂₇H₃₃ClO₆
• 分子量: 489.008
• InChiKey: HORXGDGTNRNSRV-UHFFFAOYSA-N

物化性质

• 沸点：
  587.7±50.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Ethyl 3-<4-<(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl)methoxy>phenyl>-2-chloropropionate 生成 曲格列酮
  参考文献：
  名称：

  YOSHIOKA, TAKAO;KITAZAWA, EIICI;KURUMADA, TOMOYUKI;YAMAZAKI, MITSUO;HASEG+

  摘要：

  DOI：
• 作为产物：
  描述：

  6-Acetoxy-2-<(4-aminophenoxy)methyl>-2,5,7,8-tetramethylchroman 生成 Ethyl 3-<4-<(6-acetoxy-2,5,7,8-tetramethylchroman-2-yl)methoxy>phenyl>-2-chloropropionate
  参考文献：
  名称：

  YOSHIOKA, TAKAO;KITAZAWA, EIICI;KURUMADA, TOMOYUKI;YAMAZAKI, MITSUO;HASEG+

  摘要：

  DOI：

文献信息

• Thiazolidine derivatives, their preparation and use
  申请人：Sankyo Company, Limited

  公开号：US05104888A1

  公开（公告）日：1992-04-14

  Compounds of formula (I): ##STR1## (in which R.sup.1 -R.sup.7 are hydrogen or various organic groups, n is 1-10, Ar is an aromatic group, U is CH.sub.2 or a carbon atom doubly bonded to either one of its adjacent carbons, and W is >CH.sub.2, >C.dbd.O, >CHOH, >C.dbd.NOH or various derivatives thereof) have the ability to lower the levels of blood lipid peroxides and blood sugars and to inhibit the activity of aldose reductase; they may be used therapeutically for these purposes.

  公式(I)的化合物：##STR1##（其中R.sup.1 -R.sup.7是氢或各种有机基团，n是1-10，Ar是芳香族基团，U是CH.sub.2或一个碳原子与任一相邻的碳原子双键连接，W是>CH.sub.2，>C.dbd.O，>CHOH，>C.dbd.NOH或其各种衍生物）具有降低血脂过氧化物和血糖水平以及抑制醛糖还原酶活性的能力；它们可以用于这些目的的治疗。
• Thiazolidine derivatives, their preparation and compositions containing
  申请人：Sankyo Company Limited

  公开号：US04572912A1

  公开（公告）日：1986-02-25

  The compounds of formula (I): ##STR1## [in which: R.sup.1 and R.sup.2 are the same or different and each represents hydrogen or C.sub.1 -C.sub.5 alkyl; R.sup.3 represents hydrogen, an acyl group, a (C.sub.1 -C.sub.6 alkoxy)carbonyl group or an aralkyloxycarbonyl group; R.sup.4 and R.sup.5 are the same or different and each represents hydrogen, C.sub.1 -C.sub.5 alkyl or C.sub.1 -C.sub.5 alkoxy, or R.sup.4 and R.sup.5 together represent a C.sub.1 14 C.sub.4 alkylenedioxy group; n is 1, 2 or 3; W represents the --CH.sub.2 --, >CO or >CH--OR.sup.6 group (in which R.sup.6 represents any one of the atoms or groups defined for R.sup.3 and may be the same as or different from R.sup.3); and Y and Z are the same or different and each represents oxygen or imino] and pharmaceutically acceptable salts thereof have various valuable therapeutic effects on the blood system and may be prepared by a process which includes reacting a corresponding halopropionic acid derivative with thiourea.

  化合物的化学式（I）：##STR1## [其中：R.sup.1和R.sup.2相同或不同，每个代表氢或C.sub.1 -C.sub.5烷基；R.sup.3代表氢，酰基，（C.sub.1 -C.sub.6烷氧）羰基或芳基氧羰基；R.sup.4和R.sup.5相同或不同，每个代表氢，C.sub.1 -C.sub.5烷基或C.sub.1 -C.sub.5烷氧，或R.sup.4和R.sup.5一起代表C.sub.1 14 C.sub.4烷二氧基基团；n为1、2或3；W代表--CH.sub.2 --，>CO或>CH--OR.sup.6基团（其中R.sup.6代表R.sup.3定义的任一原子或基团，可能与R.sup.3相同或不同）；Y和Z相同或不同，每个代表氧或亚胺]及其药学上可接受的盐对血液系统具有各种有价值的治疗效果，并可通过将相应的卤代丙酸衍生物与硫脲反应制备。
• Studies on the Metabolism of Troglitazone to Reactive Intermediates in Vitro and in Vivo. Evidence for Novel Biotransformation Pathways Involving Quinone Methide Formation and Thiazolidinedione Ring Scission
  作者：Kelem Kassahun、Paul G. Pearson、Wei Tang、Ian McIntosh、Kwan Leung、Charles Elmore、Dennis Dean、Regina Wang、George Doss、Thomas A. Baillie

  DOI：10.1021/tx000180q

  日期：2001.1.1

  withdrawal of the product from the U.S. market. While the mechanism of this toxicity remains unknown, it is possible that chemically reactive metabolites of the drug play a causative role. In an effort to address this possibility, this study was undertaken to determine whether troglitazone undergoes metabolism in human liver microsomal preparations to electrophilic intermediates. Following incubation of

  口服抗糖尿病药曲格列酮（Rezulin）的治疗与严重的肝毒性和药物引起的肝衰竭有关，这导致该产品最近从美国市场撤出。尽管这种毒性的机理尚不清楚，但该药物的化学反应代谢物可能起着致病作用。为了解决这种可能性，进行了这项研究以确定曲格列酮在人肝微粒体制剂中是否经历代谢成亲电中间体的作用。在存在谷胱甘肽（GSH）的情况下，将曲格列酮与人肝微粒体和cDNA表达的细胞色素P450亚型一起孵育后，总共检测到5种GSH缀合物（M1-M5），并通过LC-MS / MS分析进行了初步鉴定。在两种情况下（M1和M5），加合物的结构通过NMR光谱和/或通过与合成制备的真实标准品进行比较来确认。谷胱甘肽结合物M1-M5的形成揭示了曲格列酮有两种不同的代谢活化途径，其中一种涉及取代的苯并二氢吡喃环系统氧化成反应性邻醌甲基化物衍生物，而第二种涉及新的氧化裂解。噻唑烷二酮（TZD）环，可能产生高度亲电的α-酮异氰酸酯和
• Polymorphic forms of troglitazone having enhanced anti-diabetic activity
  申请人：Dr. Reddy's Research Foundation

  公开号：US05700820A1

  公开（公告）日：1997-12-23

  Novel polymorphic forms of Troglitazone and methods for preparing the polymorphic forms of Troglitazone. The polymorphic forms of Troglitazone can be used to treat diabetic ailments.

  Troglitazone的新型多晶型形式及其制备方法。Troglitazone的多晶型形式可用于治疗糖尿病病症。
• Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
  作者：Takao Yoshioka、Takashi Fujita、Tsutomu Kanai、Yuichi Aizawa、Tomoyuki Kurumada、Kazuo Hasegawa、Hiroyoshi Horikoshi

  DOI：10.1021/jm00122a022

  日期：1989.2

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.